We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine HIV Care Integration Project

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00348868
First Posted: July 6, 2006
Last Update Posted: March 18, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
HRSA/Maternal and Child Health Bureau
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Miami
  Purpose
A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.

Condition Intervention
HIV Infection Opioid-Related Disorders Behavioral: enhanced behavioral motivation counseling Behavioral: Motivational counseling Behavioral: Standard counseling

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Miami Buprenorphine HIV Care Integration Project

Resource links provided by NLM:


Further study details as provided by University of Miami:

Primary Outcome Measures:
  • The three primary outcomes are Cessation of illicit opioid use, Reduction in high risk behavior and Improved HIV therapy adherence [ Time Frame: week 48 ]

Enrollment: 10
Study Start Date: July 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
enhanced behavioral motivation counseling
Behavioral: enhanced behavioral motivation counseling Behavioral: Motivational counseling
Active Comparator: 2 Behavioral: Standard counseling

Detailed Description:

DESIGN: A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.

DURATION: Subjects will participate in this study for approximately 48 weeks. Chart abstractions will continue for up to four years.

SAMPLE SIZE: This study will enroll 60 subjects (30 per arm) over 72 weeks.

POPULATION: HIV-1 infected opioid dependent men and women ≥18 years of age who initiate buprenorphine for the treatment of opioid dependence and who are receiving primary care for HIV-1 infection.

STRATIFICATION: Subjects will be stratified at screening based on HIV care setting (integrated HIV care vs. nonintegrated HIV care)

INTERVENTON At entry subjects will be randomized to one of the following:

ARM A: Standard drug addiction counseling + buprenorphine / naloxone

ARM B: Enhanced behavioral motivation counseling + buprenorphine / naloxone

The three primary outcomes are:

  1. Cessation of illicit opioid use
  2. Reduction in high risk behavior
  3. Improved HIV therapy adherence
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV infection
  • Receiving or seeking outpatient HIV care
  • Seeking outpatient treatment for opioid dependence and be willing to take buprenorphine
  • Meets DSM-IV criteria for opioid dependence, and be willing to stop illicit opioid use and be experiencing early symptoms of opioid withdrawal at the time that buprenorphine is given
  • Men and women age ≥ 18 years
  • Women of reproductive potential must have a negative serum or urine pregnancy test result available within 7 days prior to initiating buprenorphine
  • Within 30 days: (SGOT), ALT (SGPT), and alkaline phosphatase <=5 X ULN, Total bilirubin <= 2.5 x ULN

Exclusion Criteria:

  • Serious medical problem
  • Acute and/or severe psychiatric conditions
  • High dose methadone (>30 mg/day)
  • Documented co-dependence on alcohol and/or benzodiazepines, barbiturates
  • Chronic pain management requiring opioids
  • Pregnancy or breast-feeding
  • Imprisonment or involuntary incarceration in a medical facility for psychiatric or physical
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00348868


Locations
United States, Florida
University of Miami AIDS Clinical Reserach Unit
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
HRSA/Maternal and Child Health Bureau
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Margaret Fischl, M.D. University of Miami
  More Information

Responsible Party: Margaret A. Fischl, M.D., Unversity of Miami
ClinicalTrials.gov Identifier: NCT00348868     History of Changes
Other Study ID Numbers: A007
First Submitted: July 5, 2006
First Posted: July 6, 2006
Last Update Posted: March 18, 2008
Last Verified: April 2007

Keywords provided by University of Miami:
HIV Infection
Opioid dependence
DSM-IV criteria for opioid dependence

Additional relevant MeSH terms:
HIV Infections
Opioid-Related Disorders
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists


To Top